Abstract: The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially ?2?1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I?).

Abstract: The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present invention relates to a kit for use in said methods.

Abstract: The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present invention relates to a kit for use in said methods.

Abstract: The present invention relates to a refined and detailed molecular model of the ?2?1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially ?2?1 integrin modulators. The present invention further relates to novel ?2?1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides.

Abstract: The invention relates to sulphonamide derivatives of formula (I), where RC is selected from a group consisting of dialkylamino, NO2, CN, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkanoyl, oxazol-2-yl, oxazolylaminocarbonyl, aryl, aroyl, aryl-CH(OH)—, arylaminocarbonyl, furanyl, where the aryl, aroyl and furanyl moieties may be substituted, guanidinyl-(CH2)z—N(R?)—, Het-(CH2)z—N(R?)—, Het-CO—N(R?)—, Het-CH(OH)— and Het-CO—, where Het is an optionally substituted 4-6-membered heterocyclic ring containing one or more heteroatoms sleeted from N, S and O, R? is hydrogen or alkyl, and z is an integer 1 to 5; RA is a group of formula (A), (B), (C) or (D) as defined in the claims; and RB is hydrogen, alkyl, alkanoyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminoalkyl, mono- or dialkylaminoalkyl or Het-alkyl, where Het is as defined above.

Abstract: The present invention relates to a refined and detailed molecular model of the ?2?1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially ?2?1 integrin modulators. The present invention further relates to novel ?2?1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides.

Abstract: The invention concerns a catching device (1) between a first structure (2) and a second structure (3), characterized in that it comprises at least one bolt (5) linked to the first structure and mounted in opposition to at least one elastic return means (9) tending to bring it back to a retracted position, a stop means (10) corresponding to the second structure being adapted to maintain it in a taut state when the latter is proximate the first structure, such that when the first structure is rapidly spaced apart from the second structure, each bolt is engaged with at least one corresponding retaining means (4) so as to limit the relative spacing and, when the first structure is slowly spaced apart from the second structure, each bolt and corresponding retaining means remain separated, thereby allowing complete opening between the first structure and the second structure.